Patients with reduced left ventricular function after myocardial infarction are at risk for life-threatening ventricular arrhythmias. This randomized trial was designed to evaluate the effect of an implantable defibrillator on survival in such patients. Over the course of four years, we enrolled 1232 patients with a prior myocardial infarction and a left ventricular ejection fraction of 0.30 or less. Patients were randomly assigned in a 3:2 ratio to receive an implantable defibrillator (742 patients) or conventional medical therapy (490 patients). Invasive electrophysiological testing for risk stratification was not required. Death from any cause was the end point. The clinical characteristics at base line and the prevalence of medication use at the time of the last follow-up visit were similar in the two treatment groups. During an average follow-up of 20 months, the mortality rates were 19.8 percent in the conventional-therapy group and 14.2 percent in the defibrillator group. The hazard ratio for the risk of death from any cause in the defibrillator group as compared with the conventional-therapy group was 0.69 (95 percent confidence interval, 0.51 to 0.93; P=0.016). The effect of defibrillator therapy on survival was simila...Continue Reading
Associated Clinical Trials
New insights into pacemaker syndrome gained from hemodynamic, humoral and vascular responses during ventriculo-atrial pacing
Conflict-of-interest guidelines for a multicenter clinical trial of treatment after coronary-artery bypass-graft surgery
Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators
Report of the National Heart, Lung, and Blood Institute Special Emphasis Panel on Heart Failure Research
A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias
Detection of myocardial injury during transvenous implantation of automatic cardioverter-defibrillators
A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators
Electrophysiologic testing to identify patients with coronary artery disease who are at risk for sudden death. Multicenter Unsustained Tachycardia Trial Investigators
Sudden cardiac death risk prediction: comment on "Risk factor and prediction modeling for sudden cardiac death in women with coronary artery disease"
Association of physician certification and outcomes among patients receiving an implantable cardioverter-defibrillator
Survival of patients receiving a primary prevention implantable cardioverter-defibrillator in clinical practice vs clinical trials
Clinical implementation of guidelines for cardioverter defibrillator implantation: lost in translation?
Percutaneous mitral valve annuloplasty with the carillon mitral contour system by cardiac dimensions. A minimally invasive therapeutic option for the treatment of severe functional mitral valve regurgitation
Percutaneous cardiopulmonary support for catheter ablation of unstable ventricular arrhythmias in high-risk patients
Limits and scopes of invasive risk stratification. Do we still need programmed ventricular stimulation?
Results of recent studies in catheter ablation of ventricular tachycardias: in whom to abandon the ICD?
Experienced anesthetists indispensable. Anesthesia management for implantation of cardioverter/defibrillators
Prevalence of arrhythmias and their risk factors mid- and long-term after the arterial switch operation
Transesophageal electrophysiological evaluation of children with a history of supraventricular tachycardia in infancy
I-123-mIBG myocardial imaging for assessment of risk for a major cardiac event in heart failure patients: insights from a retrospective European multicenter study
Cardiac sympathetic nerve abnormality predicts ventricular tachyarrhythmic events in patients without conventional risk of sudden death
Metaiodobenzylguanidine (mIBG) molecular imaging in implantable cardioverter defibrillator (ICD) therapy planning: a health technology assessment issue
Cardiac resynchronization therapy for heart failure - from experimental pacing to evidence-based therapy
Indications for predismissal testing with arrhythmia-induction in patients receiving an implantable cardioverter defibrillator
Prehospital cardiac arrest: a marker for higher mortality in patients with acute myocardial infarction and moderately reduced left ventricular function: results from the MITRA plus registry
"Home monitoring" for early detection of implantable cardioverter-defibrillator failure: a single-center prospective observational study
Incessant ventricular tachycardia, refractory to catheter ablation, in an ICD patient terminated by ICD lead extraction: a case report
Hotlines and clinical trial updates presented at the German Cardiac Society Meeting 2010: FAIR-HF, CIPAMI, LIPSIA-NSTEMI, Handheld-BNP, PEPCAD III, remote ischaemic conditioning, CERTIFY, PreSCD-II, German Myocardial Infarction Registry, DiaRegis
A decade of developments in chronic heart failure treatment: a comparison of therapy and outcome in a secondary and tertiary hospital setting
Prognostic utility of T-wave alternans in a real-world population of patients with left ventricular dysfunction: the PREVENT-SCD study
Significant differences in the expected versus observed longevity of implantable cardioverter defibrillators (ICDs)
Comparing outcome of patients with coronary artery disease and dilated cardiomyopathy in ICD and CRT recipients: data from the German DEVICE-registry
Impact of intracoronary reinfusion of bone marrow-derived mononuclear progenitor cells on cardiopulmonary exercise capacity in patients with chronic postinfarction heart failure
Underdetection of ventricular tachycardia by an implantable cardioverter-defibrillator due to a locally prolonged arrhythmia cycle length
Clinical Trial Updates and Hotline Sessions presented at the European Society of Cardiology Congress 2007: (FINESSE, CARESS, OASIS 5, PRAGUE-8, OPTIMIST, GRACE, STEEPLE, SCAAR, STRATEGY, DANAMI-2, ExTRACT-TIMI-25, ISAR-REACT 2, ACUITY, ALOFT, 3CPO, PROSPECT, EVEREST, COACH, BENEFiT, MERLIN-TIMI 36, SEARCH-MI, ADVANCE, WENBIT, EUROASPIRE I-III, ARISE, getABI, RIO)
Better identification of patients who benefit from implantable cardioverter defibrillators by genotyping the G protein beta3 subunit (GNB3) C825T polymorphism
Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.
Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.
Antiarrhythmic Agents: Mechanisms of Action
Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.